ALX Oncology Holdings Inc. Common Stock (ALXO) Stock Price

ALXOStock

$2.00+75.44%52W

Market Cap$276.55M

P/E—

PEG Ratio—

Div yield—

Beta0.45

ALXO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.30%

Price vs S&P 500 (4W)2.09%

VGM Score63.86

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)1.67x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.58

Price vs S&P 500 (YTD)64.17%

Gross Margin (TTM)9.02%

Net Profit Margin (TTM)-753.55%

EPS (TTM)$-1.49

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-1.49

EPS (Annual)$-2.60

ROI (Annual)-106.30%

Gross Margin (Annual)9.32%

Cash / Share (Quarterly)$1.04

ROA (Last FY)-91.22%

EBITD / Share (TTM)$-1.36

ROE (5Y Avg)-56.73%

Operating Margin (TTM)-731.97%

Cash Flow / Share (Annual)$-2.31

P/B Ratio1.80x

P/B Ratio (Quarterly)1.78x

Net Income / Employee (Annual)$-3,139,500

Net Interest Coverage (TTM)-8347.00x

ROA (TTM)-85.57%

EPS Incl Extra (Annual)$-2.60

Current Ratio (Annual)7.05x

Quick Ratio (Quarterly)6.99x

3-Month Avg Trading Volume1.22M

52-Week Price Return75.44%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.10

P/S Ratio (Annual)230.85x

Asset Turnover (Annual)0.00x

52-Week High$2.66

EPS Excl Extra (Annual)$-2.60

CapEx CAGR (5Y)47.86%

26-Week Price Return-18.37%

Quick Ratio (Annual)6.78x

13-Week Price Return5.82%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)7.21x

Enterprise Value$249.96M

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-3855.93%

Cash / Share (Annual)$2.42

3-Month Return Std Dev76.98%

Net Income / Employee (TTM)$-2,066,700

ROE (Last FY)-118.42%

Net Interest Coverage (Annual)-54.49x

EPS Basic Excl Extra (Annual)$-2.60

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-1.49

ROI (TTM)-107.13%

P/S Ratio (TTM)74.43x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.45

Price vs S&P 500 (52W)56.88%

Year-to-Date Return76.99%

5-Day Price Return0.50%

EPS Normalized (Annual)$-2.60

ROA (5Y Avg)-46.04%

Net Profit Margin (Annual)-3876.27%

Month-to-Date Return3.09%

Cash Flow / Share (TTM)$-3.54

EBITD / Share (Annual)$-2.71

Operating Margin (Annual)-3752.54%

LT Debt / Equity (Annual)0.05x

ROI (5Y Avg)-52.96%

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-1.49

P/TBV (Quarterly)2.61x

P/B Ratio (Annual)0.77x

Pretax Margin (TTM)-753.01%

Book Value / Share (Annual)$2.15

Price vs S&P 500 (13W)3.87%

Beta0.45x

Revenue / Share (TTM)$0.00

ROE (TTM)-124.06%

52-Week Low$0.96

mGradeB

vgmGradeB

ALXO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.16	-$0.11	+32.46%(+$0.05)
Q1 2026	May 8, 2026	-$0.16	-$0.15	+6.82%(+$0.01)
Q4 2025	Feb 27, 2026	-$0.32	-$0.37	-15.54%(-$0.05)
Q3 2025	Nov 7, 2025	-$0.37	-$0.41	-10.07%(-$0.04)
Q2 2025	Aug 12, 2025	-$0.31	-$0.44	-43.10%(-$0.13)

ALXO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.08

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALXOALX Oncology Holdings Inc. Common Stock	—	—	B	$2.00
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About ALX Oncology Holdings Inc. Common Stock

ALX Oncology is a clinical-stage immuno-oncology company developing CD47-blocking therapies to enhance the immune system's ability to recognize and eliminate cancer cells. The company's lead program, evorpacept, is in phase 1 and 2 clinical trials and targets the CD47 "don't eat me" signal that allows cancer cells to evade immune detection. ALX's approach leverages protein engineering expertise to achieve high CD47 affinity while avoiding the hematologic toxicities that limit other CD47-blocking strategies.